Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

8233 ARTÍCULOS , VIENDO DEL 2956 AL 2970

Evidence-based prevention of Alzheimer's disease: systematic review and meta-analysis of 243 observational prospective studies and 153 randomised controlled trials

Yu JT, Xu W, Tan CC, Andrieu S, Suckling J, Evangelou E, Pan A, Zhang C, Jia J, Feng L, Kua EH, Wang YJ, Wang HF, Tan MS, Li JQ, Hou XH, Wan Y, Tan L, Mok V, Tan L, Dong Q, Touchon J, Gauthier S, Aisen PS, Vellas B.

J Neurol Neurosurg Psychiatry. 2020 Nov;91(11):1201-1209. doi: 10.1136/jnnp-2019-321913. Epub 2020 Jul 20.

Brain cell somatic gene recombination and its phylogenetic foundations

Kaeser G, Chun J.

J Biol Chem. 2020 Sep 4;295(36):12786-12795. doi: 10.1074/jbc.REV120.009192. Epub 2020 Jul 22.

Brain angiotensin II and angiotensin IV receptors as potential Alzheimer's disease therapeutic targets

Royea J, Hamel E.

Geroscience. 2020 Oct;42(5):1237-1256. doi: 10.1007/s11357-020-00231-y. Epub 2020 Jul 22.

An evaluation on potential anti-inflammatory effects of β-lapachone

Mokarizadeh N, Karimi P, Kazemzadeh H, Fathi Maroufi N, Sadigh-Eteghad S, Nikanfar S, Rashtchizadeh N.

Int Immunopharmacol. 2020 Oct;87:106810. doi: 10.1016/j.intimp.2020.106810. Epub 2020 Jul 21.

Multitarget Therapeutic Strategies for Alzheimer's Disease: Review on Emerging Target Combinations

Maramai S, Benchekroun M, Gabr MT, Yahiaoui S.

Biomed Res Int. 2020 Jun 30;2020:5120230. doi: 10.1155/2020/5120230. eCollection 2020.

Perspectives for New and More Efficient Multifunctional Ligands for Alzheimer's Disease Therapy

Zagórska A, Jaromin A.

Molecules. 2020 Jul 23;25(15):3337. doi: 10.3390/molecules25153337.

Cyclic Nucleotides Signaling and Phosphodiesterase Inhibition: Defying Alzheimer's Disease

Sharma VK, Singh TG, Singh S.

Curr Drug Targets. 2020;21(13):1371-1384. doi: 10.2174/1389450121666200727104728.

Privileged Pharmacophore of FDA Approved Drugs in Combination with Chalcone Framework: A New Hope for Alzheimer's Treatment

Mathew B.

Comb Chem High Throughput Screen. 2020;23(9):842-846. doi: 10.2174/1386207323999200728122627.

Brain insulin resistance in Alzheimer's disease and related disorders: mechanisms and therapeutic approaches

Kellar D, Craft S.

Lancet Neurol. 2020 Sep;19(9):758-766. doi: 10.1016/S1474-4422(20)30231-3. Epub 2020 Jul 27.

Transcription factor NRF2 as a promising therapeutic target for Alzheimer's disease

Qu Z, Sun J, Zhang W, Yu J, Zhuang C.

Free Radic Biol Med. 2020 Nov 1;159:87-102. doi: 10.1016/j.freeradbiomed.2020.06.028. Epub 2020 Jul 28.

Antidepressant Use and Progression of Mild to Moderate Alzheimer's Disease: Results from the European ICTUS Cohort

Abdeljalil AB, de Mauléon A, Baziard M, Vellas B, Lapeyre-Mestre M, Soto M.

J Am Med Dir Assoc. 2021 Feb;22(2):433-439. doi: 10.1016/j.jamda.2020.06.028. Epub 2020 Jul 28.

Status and future directions of clinical trials in Alzheimer's disease

Plascencia-Villa G, Perry G.

Int Rev Neurobiol. 2020;154:3-50. doi: 10.1016/bs.irn.2020.03.022. Epub 2020 Jul 20.

P38α MAPK Signaling-A Robust Therapeutic Target for Rab5-Mediated Neurodegenerative Disease

Germann UA, Alam JJ.

Int J Mol Sci. 2020 Jul 31;21(15):5485. doi: 10.3390/ijms21155485.

Anti-amyloid-β protein agents for the treatment of Alzheimer's disease: an update on emerging drugs

Lozupone M, Solfrizzi V, D'Urso F, Di Gioia I, Sardone R, Dibello V, Stallone R, Liguori A, Ciritella C, Daniele A, Bellomo A, Seripa D, Panza F.

Expert Opin Emerg Drugs. 2020 Sep;25(3):319-335. doi: 10.1080/14728214.2020.1808621. Epub 2020 Aug 20.

A multitude of signaling pathways associated with Alzheimer's disease and their roles in AD pathogenesis and therapy

Gadhave K, Kumar D, Uversky VN, Giri R.

Med Res Rev. 2021 Sep;41(5):2689-2745. doi: 10.1002/med.21719. Epub 2020 Aug 11.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias